The Discounted Cash Flow (DCF) valuation of Mirati Therapeutics Inc (MRTX) is (1,740.37) USD. With the latest stock price at 58.70 USD, the upside of Mirati Therapeutics Inc based on DCF is -3064.9%.
Based on the latest price of 58.70 USD and our DCF valuation, Mirati Therapeutics Inc (MRTX) is a sell. selling MRTX stocks now will result in a potential gain of 3064.9%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.3% - 7.5% | 6.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (15,334.92) - (937.42) | (1,740.37) |
| Upside | -26224.2% - -1697.0% | -3064.9% |